Targeting DNA damage response pathways has emerged as a promising anticancer strategy over the past decade; one case in which we have good insight is the synthetic lethality of PARP inhibitors and genetic HR deficiency caused by BRCA1 or BRCA2 mutations34–36. This evidence concerns the gene BRCA1 and hyperinsulinemic hypoglycemia, familial, 4.